Neurosense Therapeutics Ltd. Statistics
Want to see NRSN full AI Analyst Report?
Neurosense Therapeutics Ltd. (NRSN) Stock Statistics & Valuation Metrics
Total Valuation
Neurosense Therapeutics Ltd. has a market cap or net worth of $3.21M. The enterprise value is $24.53M.
- Market Cap
- $3.21M
- Enterprise Value
- $24.53M
Share Statistics
Neurosense Therapeutics Ltd. has 1,896,902 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 1,896,902
- Owned by Insiders
- 18.61%
- Owned by Institutions
- 0.25%
Financial Efficiency
Neurosense Therapeutics Ltd.’s return on equity (ROE) is 7.13 and return on invested capital (ROIC) is 797.48%.
- Return on Equity (ROE)
- 7.13
- Return on Assets (ROA)
- -10.82
- Return on Invested Capital (ROIC)
- 797.48%
- Return on Capital Employed (ROCE)
- 7.45
- Revenue Per Employee
- 0
- Profits Per Employee
- -654.41K
- Employee Count
- 17
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Neurosense Therapeutics Ltd. is -0.24. Neurosense Therapeutics Ltd.’s PEG ratio is -0.06.
- PE Ratio
- -0.24
- PS Ratio
- 0.00
- PB Ratio
- -1.03
- Price to FCF
- -0.87
- Price to Operating Cash Flow
- -0.59
- PEG Ratio
- -0.06
Income Statement
In the last 12 months, Neurosense Therapeutics Ltd. had revenue of 0 and earned -11.13M in profits. Earnings per share was -8.80.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -11.09M
- Pretax Income
- -11.13M
- Net Income
- -11.13M
- EBITDA
- -11.11M
- Earnings Per Share (EPS)
- -8.80
Cash Flow
In the last 12 months, operating cash flow was -3.67M and capital expenditures -3,000, giving a free cash flow of -3.68M billion.
- Operating Cash Flow
- -3.67M
- Free Cash Flow
- -3.68M
- Free Cash Flow per Share
- -2.88
Dividends & Yields
Neurosense Therapeutics Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -114.67%
- Earnings Yield
- -406.08%
Stock Price Statistics
- Beta
- 1.25
- 52-Week Price Change
- -90.79%
- 50-Day Moving Average
- 4.31
- 200-Day Moving Average
- 12.00
- Relative Strength Index (RSI)
- 31.39
- Average Volume (3m)
- 32.65K
Important Dates
Neurosense Therapeutics Ltd. upcoming earnings date is Dec 02, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Sep 25, 2026
- Next Earnings Date
- Dec 02, 2026
- Ex-Dividend Date
- ―
Financial Position
Neurosense Therapeutics Ltd. as a current ratio of 0.31, with Debt / Equity ratio of -10.90%
- Current Ratio
- 0.31
- Quick Ratio
- 0.31
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- -0.00
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Neurosense Therapeutics Ltd. has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Neurosense Therapeutics Ltd. EV to EBITDA ratio is -0.34, with an EV/FCF ratio of -0.81.
- EV to Sales
- 0.00
- EV to EBITDA
- -0.34
- EV to Free Cash Flow
- -0.81
- EV to Operating Cash Flow
- -0.81
Balance Sheet
Neurosense Therapeutics Ltd. has $166.00K in cash and marketable securities with $170.00K in debt, giving a net cash position of -$4,000.00 billion.
- Cash & Marketable Securities
- $166.00K
- Total Debt
- $170.00K
- Net Cash
- -$4,000.00
- Net Cash Per Share
- $0.00
- Tangible Book Value Per Share
- -$1.22
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Neurosense Therapeutics Ltd. is $3.50, which is 11.43% higher than the current price. The consensus rating is Neutral
- Price Target
- $3.50
- Price Target Upside
- 107.10% Upside
- Analyst Consensus
- Neutral
- Analyst Count
- 2
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- ―
Scores
- Smart Score
- ―
- AI Score
- 42
